SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen’s (JOBS) Bone Drug May Face Delays In FDA Decision

October 16, 2009 | 
1 min read
Bookmark and Share

NEW YORK (Dow Jones)--Biotech investors had circled Oct. 19 as the day that Amgen Inc.'s (AMGN) osteoporosis drug denosumab gets approved, but they may have to wait longer.
Regulatory
Amgen
MORE ON THIS TOPIC
Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus. 3d rendering
IN PARTNERSHIP WITH VIVA BIOTECH
Cyclic peptides open new drug frontiers, if manufacturing can keep up
September 14, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
Creative background as a blue abstract extreme perspective design element representing time travel or Psychedelic and hallucinogenic consciousness trip as a 3D illustration.
Psychedelics
Psychedelic therapies ride wave of public favor into FDA hearing
September 14, 2026
 · 
3 min read
 · 
Michael Gibney
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
September 10, 2026
 · 
3 min read
 · 
Heather McKenzie
Vector cartoon illustration of a business team standing at a crossroad with multiple arrows, discussing and choosing the right path toward success and future opportunities.
Drug pricing
Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’
September 10, 2026
 · 
4 min read
 · 
Annalee Armstrong